Optimising Therapeutic Options for Bile Duct Cancer in the Era of Molecular Profiling, Immunotherapy and Pharmacogenomics

Résumé fourni par la source

This chapter explores the evolving landscape of bile duct cancer (cholangiocarcinoma, CCA) treatment, with a particular focus on the evolving landscape of systemic therapy driven by advances in molecular profiling, immunotherapy and pharmacogenomics. As new diagnostic technologies and precision therapies become available, there is increasing scope to personalise care based on tumour biology and individual patient characteristics. The chapter presents a critical review of current standard treatments and unmet needs, followed by an in-depth discussion of emerging therapies, including key molecular targets such as IDH1, FGFR2 and HER2, and the expanding role of immunotherapy. It also evaluates how pharmacogenomic tools and toxicity-monitoring innovations are helping to individualise treatment further. The chapter concludes with proposals for integrated treatment algorithms and strategies to optimise access, effectiveness, and patient outcomes in clinical practice.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.